Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology

Volumn 67, Issue 1, 2012, Pages 76-85

  Kimball, Alexa B ^a   Szapary, Philippe ^b,c   Mrowietz, Ulrich ^d   Reich, Kristian ^e   Langley, Richard G ^f   You, Yin ^b   Hsu, Ming Chun ^b   Yeilding, Newman ^b   Rader, Daniel J ^c   Mehta, Nehal N ^c,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTOCOR INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e DERMATOLOGIKUM HAMBURG   (Germany)

^f DALHOUSIE UNIVERSITY   (Canada)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cardiovascular risk; diabetes; hyperlipidemia; hypertension; psoriasis; underdiagnosis; undertreatment; ustekinumab

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METFORMIN; USTEKINUMAB;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIAC PATIENT; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; SCREENING;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PSORIASIS; RISK FACTORS;

EID: 84862297697     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.06.035     Document Type: Article

References (56)

1. J. Koo Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment Dermatol Clin 14 1996 485 496 (Pubitemid 26249398)
2. M.P. Schon, and W.H. Boehncke Psoriasis N Engl J Med 352 2005 1899 1912 (Pubitemid 40627816)
3. F.O. Nestle, D.H. Kaplan, and J. Barker Psoriasis N Engl J Med 361 2009 496 509
4. R.G. Langley, S.R. Feldman, C. Han, B. Schenkel, P. Szapary, and M.C. Hsu Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial J Am Acad Dermatol 63 2009 457 465
5. J. Hong, B. Koo, and J. Koo The psychosocial and occupational impact of chronic skin disease Dermatol Ther 21 2008 54 59 (Pubitemid 351342175)
6. National Psoriasis Foundation. Home page. Available from: URL: http://www.psoriasis.org. Accessed October 20, 2010.
7. T. Henseler, and E. Christophers Disease concomitance in psoriasis J Am Acad Dermatol 32 1995 982 986
8. U. Mrowietz, J.T. Elder, and J. Barker The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients Arch Dermatol Res 298 2006 309 319
9. A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel, and J.M. Gelfand Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 2006 829 835 (Pubitemid 44556851)
10. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741 (Pubitemid 44547793)
11. J.M. Gelfand, E.D. Dommasch, D.B. Shin, R.S. Azfar, S.K. Kurd, and X. Wang The risk of stroke in patients with psoriasis J Invest Dermatol 129 2009 2411 2418
12. N.N. Mehta, R.S. Azfar, D.B. Shin, A.L. Neimann, A.B. Troxel, and J.M. Gelfand Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database Eur Heart J 31 2010 1000 1006
13. J.M. Gelfand, A.B. Troxel, J.D. Lewis, S.K. Kurd, D.B. Shin, and X. Wang The risk of mortality in patients with psoriasis: results from a population-based study Arch Dermatol 143 2007 1493 1499 (Pubitemid 350277763)
14. K. Abuabara, R.S. Azfar, D.B. Shin, A.L. Neimann, A.B. Troxel, and J.M. Gelfand Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the United Kingdom Br J Dermatol 163 2010 586 592
15. S. Gerdes, V.A. Zahl, H. Knopf, M. Weichenthal, and U. Mrowietz Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis Br J Dermatol 159 2008 1116 1123
16. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, and D.B. Hunninglake Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
17. C.N. Bairey Merz, M.J. Alberts, G.J. Balady, C.M. Ballantyne, K. Berra, and H.R. Black ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease J Am Coll Cardiol 54 2009 1336 1363
18. C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, and Y. Wang PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674 (Pubitemid 351671883)
19. K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, and N. Yeilding PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684 (Pubitemid 351671884)
20. C.E.M. Griffiths, B.E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, and N. Yeilding Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
21. J.I. Cleeman Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497 (Pubitemid 32433843)
22. World Health Organization, Department of Noncommunicable Disease Surveillance, Geneva. Report of a WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus. 1999;1-59.
23. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
24. American Diabetes Association Standards of medical care in diabetes-2009 Diabetes Care 32 2009 S13 S61
25. C. Rosendorff, H.R. Black, C.P. Cannon, B.J. Gersh, J. Gore, and J.L. Izzo American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation 115 2007 2761 2788 (Pubitemid 46842793)
26. P.W. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, and W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847 (Pubitemid 28213628)
27. J.M. Gelfand, R.S. Stern, T. Nijsten, S.R. Feldman, J. Thomas, and J. Kist The prevalence of psoriasis in African Americans: results from a population-based study J Am Acad Dermatol 52 2005 23 26 (Pubitemid 40038931)
28. Y.T. Chang, T.J. Chen, P.C. Liu, Y.C. Chen, Y.J. Chen, and Y.L. Huang Epidemiological study of psoriasis in the national health insurance database in Taiwan Acta Derm Venereol 89 2009 262 266
29. American Heart Association Heart disease and stroke statistics-2010 update 2010 American Heart Association Dallas (TX) p. 1-36
30. J.R. Brown, and G.T. O'Connor Coronary heart disease and prevention in the United States N Engl J Med 362 2010 2150 2153
31. S. Mottillo, K.B. Filion, J. Genest, L. Joseph, L. Pilote, and P. Poirier The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis J Am Coll Cardiol 56 2010 1113 1132
32. Centers for Disease Control and Prevention Cigarette smoking among adults and trends in smoking cessation-United States, 2008 Morb Mortal Wkly Rep 58 2009 1227 1232
33. A.B. Kimball, A. Guerin, D. Latremouille-Viau, A.P. Yu, S. Gupta, and Y. Bao Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis Am J Med 123 2010 350 357
34. M.J. Peters, D.P. Symmons, D. McCarey, B.A.C. Dijkmans, P. Nicola, and T.K. Kvien EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis Ann Rheum Dis 69 2010 325 331
35. J.A. Kaye, L. Li, and S.S. Jick Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis Br J Dermatol 159 2008 895 902
36. J.R. Elliott, and S. Manzi Cardiovascular risk assessment and treatment in systemic lupus erythematosus Best Pract Res Clin Rheumatol 23 2009 481 494
37. S. Agarwal, J.R. Elliott, and S. Manzi Atherosclerosis risk factors in systemic lupus erythematosus Curr Rheumatol Rep 11 2009 241 247
38. C. Han, D.W. Robinson Jr., M.V. Hackett, L.C. Paramore, K.H. Fraeman, and M.V. Bala Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis J Rheumatol 33 2006 2167 2172 (Pubitemid 44749774)
39. M.P. Reilly, M.L. Wolfe, T. Rhodes, C. Girman, N. Mehta, and D.J. Rader Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis Circulation 110 2004 803 809 (Pubitemid 39096007)
40. J.M. Dekker, C. Girman, T. Rhodes, G. Nijpels, C.D. Stehouwer, and L.M. Bouter Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn study Circulation 112 2005 666 673 (Pubitemid 41099045)
41. V.E. Friedewald Jr., J.C. Cather, K.B. Gordon, A. Kavanaugh, P.M. Ridker, and W.C. Roberts The editor's roundtable: psoriasis, inflammation, and coronary artery disease Am J Cardiol 101 2008 1119 1126
42. C. Triplitt Improving treatment success rates for type 2 diabetes: recommendations for a changing environment Am J Manag Care 16 2010 S195 S200
43. S. Malik, V. Lopez, R. Chen, W. Wu, and N.D. Wong Undertreatment of cardiovascular risk factors among persons with diabetes in the United States Diabetes Res Clin Pract 77 2007 126 133 (Pubitemid 46590472)
44. B. Zafrir, and S. Cohen Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: undertreatment and rationale for lipid-lowering therapy Eur J Intern Med 17 2006 495 499 (Pubitemid 44708735)
45. R.H. Chapman, A.A. Petrilla, L. Berman, J.S. Benner, and S.S. Tang Are high-risk hypertensive patients being prescribed concomitant statin therapy? A retrospective cohort study Am J Cardiovasc Drugs 9 2009 299 308
46. T.M. MacDonald, S.V. Morant, and E. Mozaffari Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United Kingdom J Hum Hypertens 21 2007 925 933 (Pubitemid 350167097)
47. K.H. Costenbader, E. Wright, M.H. Liang, and E.W. Karlson Cardiac risk factor awareness and management in patients with systemic lupus erythematosus Arthritis Rheum 51 2004 983 988 (Pubitemid 39648192)
48. K. Maksimowicz-McKinnon, F. Selzer, S. Manzi, K.E. Kip, S.R. Mulukutla, and O.C. Marroquin Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute Dynamic Registry Circ Cardiovasc Interv 1 2008 201 208
49. T.E. Toms, V.F. Panoulas, K.M. Douglas, H. Griffiths, N. Sattar, and J.P. Smith Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 69 2010 683 688
50. C.P. Chung, A. Oeser, I. Avalos, P. Raggi, and C.M. Stein Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus Lupus 15 2006 562 569 (Pubitemid 44661742)
51. C.P. Chung, A. Oeser, I. Avalos, T. Gebretsadik, A. Shintani, and P. Raggi Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis Arthritis Res Ther 8 2006 R186
52. A.K. Marma, J.D. Berry, H. Ning, S.D. Persell, and D.M. Lloyd-Jones Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006 Circ Cardiovasc Qual Outcomes 3 2010 8 14
53. T. Nijsten, and M. Wakkee Complexity of the association between psoriasis and comorbidities J Invest Dermatol 129 2009 1601 1603
54. Z. Mosenifar Population issues in clinical trials Proc Am Thorac Soc 4 2007 185 188
55. E.L. Ding, N.R. Powe, J.E. Manson, N.S. Sherber, and J.B. Braunstein Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials Arch Intern Med 167 2007 905 912 (Pubitemid 46762752)
56. J.B. Braunstein, N.S. Sherber, S.P. Schulman, E.L. Ding, and N.R. Powe Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials Medicine (Baltimore) 87 2008 1 9